Loading...
A166480 logo

CORESTEMCHEMON Inc.KOSDAQ:A166480 Stock Report

Market Cap ₩84.2b
Share Price
₩1.90k
My Fair Value
n/a
1Y-84.4%
7D32.6%
Portfolio Value
​
View

CORESTEMCHEMON Inc.

KOSDAQ:A166480 Stock Report

Market Cap: ₩84.2b

CORESTEMCHEMON (A166480) Stock Overview

A bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. More details

A166480 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Earnings have declined by 8.7% per year over past 5 years

Highly volatile share price over the past 3 months compared to the KR market

Does not have a meaningful market cap (₩84B)


A166480 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

CORESTEMCHEMON Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for CORESTEMCHEMON
Historical stock prices
Current Share Price₩1,898.00
52 Week High₩15,570.00
52 Week Low₩1,014.00
Beta0.63
1 Month Change33.57%
3 Month Change-16.02%
1 Year Change-84.43%
3 Year Change-80.21%
5 Year Change-91.99%
Change since IPO-95.44%

Recent News & Updates

Investors Don't See Light At End Of CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Tunnel

Dec 03
Investors Don't See Light At End Of CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Tunnel

Why Investors Shouldn't Be Surprised By CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 40% Share Price Plunge

Aug 19
Why Investors Shouldn't Be Surprised By CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 40% Share Price Plunge

Recent updates

Investors Don't See Light At End Of CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Tunnel

Dec 03
Investors Don't See Light At End Of CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Tunnel

Why Investors Shouldn't Be Surprised By CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 40% Share Price Plunge

Aug 19
Why Investors Shouldn't Be Surprised By CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 40% Share Price Plunge

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Price Is Right But Growth Is Lacking

Apr 14
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Price Is Right But Growth Is Lacking

Is CORESTEMCHEMON (KOSDAQ:166480) Using Too Much Debt?

Feb 20
Is CORESTEMCHEMON (KOSDAQ:166480) Using Too Much Debt?

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Popularity With Investors Under Threat As Stock Sinks 25%

Dec 09
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Popularity With Investors Under Threat As Stock Sinks 25%

Is CORESTEMCHEMON (KOSDAQ:166480) A Risky Investment?

Nov 01
Is CORESTEMCHEMON (KOSDAQ:166480) A Risky Investment?

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 27% Price Boost Is Out Of Tune With Revenues

Sep 24
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 27% Price Boost Is Out Of Tune With Revenues

Would CORESTEMCHEMON (KOSDAQ:166480) Be Better Off With Less Debt?

Aug 03
Would CORESTEMCHEMON (KOSDAQ:166480) Be Better Off With Less Debt?

What CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 26% Share Price Gain Is Not Telling You

Jun 08
What CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 26% Share Price Gain Is Not Telling You

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Shares Bounce 25% But Its Business Still Trails The Industry

Mar 05
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Shares Bounce 25% But Its Business Still Trails The Industry

Does CORESTEM (KOSDAQ:166480) Have A Healthy Balance Sheet?

Apr 12
Does CORESTEM (KOSDAQ:166480) Have A Healthy Balance Sheet?

If You Had Bought CORESTEM (KOSDAQ:166480) Shares A Year Ago You'd Have Earned 59% Returns

Feb 16
If You Had Bought CORESTEM (KOSDAQ:166480) Shares A Year Ago You'd Have Earned 59% Returns

Corestem (KOSDAQ:166480) Has Debt But No Earnings; Should You Worry?

Dec 25
Corestem (KOSDAQ:166480) Has Debt But No Earnings; Should You Worry?

Shareholder Returns

A166480KR BiotechsKR Market
7D32.6%-0.9%4.1%
1Y-84.4%50.0%65.7%

Return vs Industry: A166480 underperformed the KR Biotechs industry which returned 50% over the past year.

Return vs Market: A166480 underperformed the KR Market which returned 65.7% over the past year.

Price Volatility

Is A166480's price volatile compared to industry and market?
A166480 volatility
A166480 Average Weekly Movement13.8%
Biotechs Industry Average Movement8.1%
Market Average Movement5.4%
10% most volatile stocks in KR Market11.4%
10% least volatile stocks in KR Market2.6%

Stable Share Price: A166480's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A166480's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
2003n/aKyung-Suk Kimwww.corestem.com

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases.

CORESTEMCHEMON Inc. Fundamentals Summary

How do CORESTEMCHEMON's earnings and revenue compare to its market cap?
A166480 fundamental statistics
Market cap₩84.20b
Earnings (TTM)-₩12.92b
Revenue (TTM)₩20.13b
4.2x
P/S Ratio
-6.5x
P/E Ratio

Is A166480 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A166480 income statement (TTM)
Revenue₩20.13b
Cost of Revenue₩24.09b
Gross Profit-₩3.96b
Other Expenses₩8.96b
Earnings-₩12.92b

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-291.32
Gross Margin-19.70%
Net Profit Margin-64.20%
Debt/Equity Ratio127.0%

How did A166480 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/06 20:48
End of Day Share Price 2025/12/05 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CORESTEMCHEMON Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Byung Hwa HanEugene Investment & Securities Co Ltd.
Jiyong LeeShinhan Investment Corp.
Choongwoo SeoSK Securities Co., Ltd.